according to this article Neuren did do animal testing for aged memory loss. Given the great results (according to this article) I am curious why this wouldn't have been pursued further by Neuren given the scale of the potential market?
https://www.biospace.com/article/releases/neuren-pharmaceuticals-limited-s-third-lead-drug-candidate-nnz-2591-proves-effective-at-reversing-memory-loss-/
Ann: Neuren completes Phelan-McDermid syndrome Phase 2 trial, page-29
-
- There are more pages in this discussion • 23 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.17 |
Change
0.070(0.35%) |
Mkt cap ! $2.578B | |||
| Open | High | Low | Value | Volume |
| $20.39 | $20.53 | $20.14 | $4.102M | 202.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 249 | $20.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.31 | 790 | 1 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |